Boston, MA & Singapore - October 3, 2022 - AIM Biotech announced the launch of the organiX System, a lab tool to closely model human disease by adding vascularization and immune competence to organoids, spheroids and tumor biopsies. Adding vascularization and immune cells to a disease model creates a more defined and tunable microenvironment to more closely emulate the complexity of human physiology. This is all packaged together in an easy-to-use tool, designed around a universal plate format, so labs and researchers can more easily study diseases, more accurately predict success of investigational treatments and better predict optimal patient therapies.
To view the full announcement, including downloadable images, bios, and more, click here.
- OrganiX makes it possible to emulate and study more complex and relevant human disease models with organoids and biopsies by incorporating vasculature and immune cells
- Vascularization, the resulting inter-tissue communication, and the affect of immune cells enables organoids and biopsies to have a defined and tunable microenvironment for more predictive modeling, screening and patient profiling.
- As a result, labs can now generate a deeper understanding of human disease, design superior therapies, more accurately predict clinical success of investigational therapies, and better tailor treatments to patients.
Click image above to view full announcement.
About AIM Biotech
AIM Biotech is a biotechnology company at the forefront of transforming drug discovery into a more targeted, predictable and less expensive endeavor. The company's patented microfluidic devices and assays in critical therapeutic areas bring actual human physiological context to drug discovery and cancer therapy selection, enabling insights not previously possible through conventional approaches. AIM Biotech is located in Singapore and Boston, MA.
Media & Investors
Source: AIM Biotech
Distributed by: Reportable, Inc.